Impact of Freeze-thaw Cycles and Storage Time on Plasma Samples Used in Mass Spectrometry Based Biomarker Discovery Projects by Mitchell, Breeana L et al.
Cancer Informatics 2005:1 98-104 98
ORIGINAL RESEARCH
Correspondence: Paul Lampe, plampe@fhcrc.org
Impact of Freeze-thaw Cycles and Storage Time on Plasma 
Samples Used in Mass Spectrometry Based Biomarker 
Discovery Projects
Breeana L Mitchell
a,b, Yutaka Yasui
e, Christopher I Li
a,c, Annette L. Fitzpatrick
c, 
Paul D Lampe
a,b,d
Public Health Sciences
a, Fred Hutchinson Cancer Research Center, Molecular and Cellular Biology 
Program
b, Departments of Epidemiology
c, and Pathobiology
d, University of Washington, Department 
of Public Health Sciences
e University of Alberta
Abstract: Mass spectrometry approaches to biomarker discovery in human ﬂ  uids have received a great deal of attention in 
recent years. While mass spectrometry instrumentation and analysis approaches have been widely investigated, little atten-
tion has been paid to how sample handling can impact the plasma proteome and therefore inﬂ  uence biomarker discovery. 
We have investigated the effects of two main aspects of sample handling on MALDI-TOF data: repeated freeze-thaw cycles 
and the effects of long-term storage of plasma at –70°C. Repeated freeze-thaw cycles resulted in a trend towards increasing 
changes in peak intensity, particularly after two thaws. However, a 4-year difference in long-term storage appears to have 
minimal effect on protein in plasma as no differences in peak number, mass distribution, or coefﬁ  cient of variation were 
found between samples. Therefore, limiting freeze/thaw cycles seems more important to maintaining the integrity of the 
plasma proteome than degradation caused by long-term storage at –70°C. 
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Introduction
Biomarkers have the potential to aid in the diagnosis and treatment of many diseases, from cancer to 
heart disease. The advent of new technologies has generated increased interest in widespread screening 
for disease biomarkers. Identifying biomarkers derived from human serum or plasma is particularly 
appealing because blood can be obtained with high patient acceptability and it is in contact with most 
tissues, thereby making it likely to contain proteins or peptides that could be used to distinguish between 
individuals with or without a particular disease.
Recent advances in mass spectrometry technologies have increased the accuracy and sensitivity of 
this tool such that it can now be practically used for the analysis of complex mixtures such as blood. 
Matrix based time-of-ﬂ  ight mass spectrometry techniques have been pursued extensively in recent years 
due to high sample throughput and ease of use. Matrix assisted laser desorption/ionization time-of-ﬂ  ight 
(MALDI-TOF) and surface enhanced laser desorption/ionization time-of-ﬂ  ight (SELDI-TOF) are 
similar methods based on the laser excitation and subsequent unique ﬂ  ight time of proteins or peptides 
in a complex mixture (Hillenkamp and Karas 1990; Hutchens 1993). Recent publications using primarily 
SELDI-TOF have reported the ability to classify certain diseases with extremely high sensitivity and 
speciﬁ  city (Adam et al. 2002; Petricoin et al. 2002b; Petricoin et al. 2002a; Banez et al. 2003; Won et 
al. 2003; Alexe et al. 2004). Despite the seeming success of early studies, mass spectrometry TOF-based 
biomarker discovery is fraught with controversy (Diamandis 2002; Diamandis 2003; Sorace and Zhan 
2003; Baggerly et al. 2004; Diamandis 2004). From the ﬁ  rst stages of sample collection to the ﬁ  nal 
stages of data analysis, the methods and techniques employed are likely to have considerable impact 
on the outcome of a study.
While careful consideration is often paid to the development of the mass spectrometry protocol and 
analysis of mass spectrometry data, most studies have not considered how the handling of the samples 
prior to mass spectrometry analysis could affect the study results. One appeal of using serum or plasma for 
biomarker discovery projects is that there are many excellent epidemiological studies that have already 
been conducted. Some of these studies have obtained blood from participants and a few have sera or 
plasma samples available from multiple time points, including samples drawn prior to disease diagnosis. 
These samples could contain a wealth of information that was inaccessible before the advances in mass Mitchell, Yasui, Li et al
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spectrometry. However, a caveat of biomarker 
discovery using mass spectrometry is that the 
technique relies on the consistency of the mass of 
proteins and peptides between samples and over 
time. Improper sample storage may lead to protein 
degradation, reducing the power of a study to detect 
differences within a population. As of yet, we are 
not aware of any studies investigating the effects 
that sample storage and handling could have on 
the outcome of biomarker discovery projects using 
mass spectrometry.
In this study, we address two aspects of sample 
storage. We used control plasma to investigate 
whether repeated freeze-thaw cycles have an effect 
on the quality of a plasma sample. Further, using 
samples obtained at two time points four years apart 
in a cohort study, we investigated the signiﬁ  cance 
of long-term storage of plasma samples at -70°C.
Methods
Longitudinal Study participants
This study utilizes blood samples obtained from 
participants of the Cardiovascular Health Study 
(CHS), an observational cohort sponsored by the 
National Heart, Lung and Blood Institute to 
investigate risk factors for cardiovascular disease 
in the elderly (Fried et al. 1991). The CHS multi-
site cohort includes 5,201 men and women aged 
65 or older who were enrolled in 1989/90 and an 
additional 687 African-Americans enrolled in 
1992/93. Informed consent was obtained from all 
study subjects. Eligibility for the CHS study was 
limited to those 65 or older who were noninstitu-
tionalized and were expected to reside in the study 
area for the next three years. Subjects were 
excluded if they were wheelchair-bound, receiving 
hospice care, or had received radiation or chemo-
therapy for cancer prior to enrollment (Tell et al. 
1993). For this sub-study, we obtained frozen 
plasma samples from 50 randomly selected CHS 
healthy subjects (dementia, cancer, and cardiovas-
cular disease-free through 1996/97) who had 
visited the CHS clinic for his/her annual examina-
tion in 1992/93 (year 5 of the study) and 1996/97 
(year 9 of the study). For each collection, blood 
was drawn in the morning following an 8-12 hour 
fast and collected into EDTA-containing tubes. 
Immediately following collection, blood was 
mixed at 4°C and spun at 3,000g for 10min at 4°C. 
Plasma samples were then frozen at –70°C and 
shipped on dry ice to the storage facility in the 
department of Pathology/Biochemistry/Medicine 
at the University of Vermont (Fried et al. 1991; 
Cushman et al. 1995).
The mean age of the 50 subjects included in this 
study was 74.4 years (+/- 3.4 years) (Table 1). 
Thirty-three subjects were female and 41 were 
white. Samples from all four CHS clinical sites 
were included.
Acetonitrile precipitation
Plasma samples were thawed and proteins were 
precipitated from a 20μl aliquot by the addition of 
an equal volume of acetonitrile. Acetonitrile treated 
samples were mixed at room temperature for 30min 
using a multi-speed vortexer at the lowest setting. 
Precipitated proteins were pelleted by centrifuga-
tion at 12,000rpm for 4min at room temperature; 
the supernatant was removed and stored on ice for 
analysis.
MALDI-TOF
A 384 well hydrophobic MALDI-TOF plate was 
pre-crystallized with sinapinic acid matrix, a super-
saturated solution of 4-hydroxy-3,5dimethoxycin-
namic acid in acetonitrile/0.1% TFA (50/50 v/v). 
Acetonitrile treated plasma samples were mixed 
with sinapinic acid in a 1:3 ratio. Each sample was 
spotted in quintuplicate onto the pre-crystallized 
plate. Mass accuracy was obtained by daily 
machine calibrations using cytochrome c [12361m/
z (+1), 6181m/z (+2)]. The plate was analyzed in 
Table 1: Characteristics of the study population
Characteristic N %
Age (years) Mean=74.4 SD=3.4
Gender
 Male 17 34.0
 Female 33 66.0
Race
 White 41 82.0
 Black 9 18.0
Clinical Site
  Wake Forest University 18 36.0
  University CA, Davis 10 20.0
 Johns  Hopkins 10 20.0
  University of Pittsburgh 12 24.0
Abbreviation: SD = Standard Deviation.100
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an Applied Biosystems Voyager mass spectrometer 
in linear mode, using a 337 nm nitrogen laser. Set-
tings were optimized using cytochrome c and were: 
laser intensity 1784, accelerating voltage 25000, 
grid voltage 23000, guide wire voltage 1250, delay 
time 325ns, low mass gate 1000, molecular mass 
range 1000 - 40,000. Final spectra were generated 
by summing spectra produced from 20 laser hits 
at up to 20 places per spot (a total of up to 400 laser 
hits per summed spectra). Individual spectra had 
to have an intensity of 3000 hits or more in order 
to be used in the summed spectra. The operator 
was blinded to the identity of the samples.
Freeze-thaw experiment
Three plasma samples from the same person were 
obtained. The samples were thawed at room tem-
perature. One aliquot of 20μl was taken from each 
sample (freeze-thaw 1). Samples were re-frozen at 
-70°C for one hour. The original samples were 
thawed again at room temperature and a second 
aliquot of 20μl was taken from each sample 
(freezethaw 2). Samples were re-frozen at -70°C 
for one hour. This cycle was repeated ﬁ  ve times to 
yield ﬁ  ve freeze-thaw samples. All samples were 
then precipitated at the same time with an equal 
volume of acetonitrile and run in quintuplicate on 
the MALDITOF instrument.
Data Analysis
Multiple methods for defining and aligning 
MALDITOF MS spectrum have been devised and 
this is an active area of research but is not the focus 
of this report. Brieﬂ  y, our method deﬁ  ned “poten-
tial peaks” by judging, at each mass/charge point, 
whether or not the protein intensity at that point is 
the highest among its nearest ± 10 points in the 
mass/chargeaxis direction. If it was the highest, 
that point was deﬁ  ned as a potential peak. The 
number of points deﬁ  ned as a peak is arbitrary and 
will vary with the width of the “window” used to 
deﬁ  ne a peak. See Yasui et al for a discussion of 
how the ± 10 points window was chosen and a 
detailed description of the method (Yasui et al. 
2003). We then estimated the noise level in the 
neighborhood of each point by a successive appli-
cation of smoothing techniques and assessed 
whether the intensity at each potential peak is at 
least 3 times higher than the noise level in its 
neighborhood. Those potential peaks that satisﬁ  ed 
this 3-fold-intensity criterion were deﬁ  ned as peaks. 
Peak alignment was performed by considering a 
window of ±0.1% of the mid mass/charge value, 
within which all peaks are considered to represent 
an identical peak: ±0.1% of mass/charge value was 
selected based on the mass/charge-axis shifting 
estimated from a QC experiment. We successively 
identiﬁ  ed the window that contained the highest 
number of peaks among all possible windows and, 
for each spectrum, assigned the mid-mass/charge 
value of the window, coupled with the maximum 
intensity value of the spectrum within the window, 
as its (aligned mass/charge, intensity) pair. This 
procedure was repeated until every peak was 
assigned an aligned mass/charge value. The end 
product of this repeated procedure is an aligned 
data matrix that consists of (aligned mass/charge, 
intensity) pairs of all spectra. The aligned spectra 
were log transformed to facilitate linear modeling 
and the aligned data matrix were normalized by 
subtracting the spectrum-speciﬁ  c mean so that the 
normalized log intensity values of every spectrum 
has zero mean.
Following the peak identiﬁ  cation/alignment and 
intensity normalization, we performed a variance-
component analysis using the following linear 
mixed model:
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are a bivariate mean-zero Gaussian random effect 
of m
th peak for i
th subject with the variance-
covariance matrix:
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representing the individual-speciﬁ  c ﬂ  uctuations 
from the means, and
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is the independent mean-zero Gaussian error term 
with variance
  τ
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Restricted maximum-likelihood estimates were 
obtained for the model parameters.
The reliability of the MALDI-TOF MS intensity 
measurements was assessed by computing coef-
ﬁ  cients of variations (CV) for each peak (log scale) 
in each time point. For the 1992/93 samples, the 
CV of m
th peak was given by
  CV
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For the 1996/97 samples, the variance and mean 
parameter estimates in the formula were replaced 
with those of 1996/97. Inference on the parameter 
provided the within-subject correlation between 
ρ provided the within-subject correlation between 
1992/93 and 1996/97 log-intensity measurements.
The analysis of the freeze-thaw experiment fol-
lowed the same peak identiﬁ  cation/alignment and 
intensity normalization procedures.
Results
Freeze-Thaw effects on MALDI Signal 
Intensity
We investigated the effect of repeated freeze-thaw 
cycles on peak intensity with each cycle. The 
change in peak intensity is reported as an absolute 
percentage value because we observed both posi-
tive and negative changes in peaks of wide ranging 
intensities (Table 2). The second, third, fourth and 
ﬁ  fth freeze-thaw cycles changed a given peak 
intensity by a median of 1.7%, 2.4%, 3.5% and 
3.1% respectively, compared to the intensity mea-
surements of the sample freeze-thawed once. While 
this indicates that the proteins are generally rela-
tively stable, the range of intensity change was 
quite high. For example 1% of the proteins changed 
by at least 67% after 4 freeze/thaw cycles (Table 2, 
99
th percentile change column). We also investi-
gated the changes in peak intensity following 
freeze-thaw cycles by mass/charge range (Table 3). 
Peaks at 20,000m/z and 10,000-20,000m/z had 
a reduction in median peak intensity while at the 
5,000-10,000m/z range there was in increase in 
peak intensity.
Effects of Long Term Storage at –70°C
There were 2,153 aligned mass/charge values at 
which peaks were identiﬁ  ed in the 500 MALDI 
spectra (50 subjects x 2 samples collected 4 years 
apart per subject x 5 replicates per sample). The 
number of peaks per spectrum in the 1992/93 
sample spectra ranged from 545 to 938 (median=636, 
25
th-percentile=611, 75
th-percentile=666), and 
from 552 to 897 (median=630, 25
th-percentile=596, 
75
th percentile=673) in the 1996/97 sample spectra 
(Table 4). These numbers of peaks per spectrum 
Table 2: Changes in peak intensity following freeze-thaw cycle
Changes in peak intensity
Number 
of freeze/ 
thaw
cycles
25
th 
percen-
tile
Median 75
th 
percen-
tile
95
th 
percen-
tile
99
th 
percen-
tile
2 0.7% 1.7% 3.0% 8.3% 19.1%
3 1.0% 2.4% 4.6% 13.8% 43.0%
4 1.3% 3.5% 7.5% 27.4% 67.6%
5 1.2% 3.1% 7.0% 25.8% 51.7%
Table 3: Changes in peak intensity following freeze-thaw cycles by 
mass/charge
Number of 
freeze/thaw 
cycles
Median changes in peak 
intensity
5,000 5,000- 
10,000
10,000- 
20,000
20,000
2 0.242% 0.687% 0.197% -0.306%
3 -0.344% 3.419% -0.621% -0.508%
4 -0.330% 3.218% -0.099% -0.295%
5 -1.201% 2.018% -0.918% -0.587%102
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are consistent with our routine analysis of 
plasma samples. When using only a single MALDI 
run for each sample, the median CV for the 2,153 
peaks in the 1992/93 samples was 14.6% 
(25
th-percentile=11.6%, 75
th-percentile=26.3%) 
and was 13.7% (25
th percentile=11.3%, 75
th-
percentile=26.5%) in the 1996/97 samples. Using 
the 5 replicates reduced the median CVs of peaks 
from 14.6% to 11.1% for the 1992/93 samples, and 
from 13.7% to 10.2% for the 1996/97 samples 
(Table 4). To calculate the correlation of intensity 
measures between the 1992/93 and the 1996/97 
samples, we estimated the correlation parameter 
using log-intensity measures. The correlations 
ranged from -0.14 to 0.95, with a median of 0.40 
and 25
th- and 75
th-percentiles of 0.32 and 0.47, 
respectively (Table 4). When the number of peaks 
was compared at different mass values there was 
no appreciable difference between the 1992/93 
samples and the 1996/97 samples at ranges 
of 5,000mass/charge, 5,000 to 10,000mass/charge 
and 10,000mass/charge (Table 5).
Discussion
Peak intensity appears to be inﬂ  uenced by repeated 
freeze-thawing of samples. While the change in 
median peak intensity is small, the impact on the 
data could be signiﬁ  cant if samples are not consis-
tently treated and/or if samples are not carefully 
tracked for freeze-thaw status. Some proteins or 
peptides are more sensitive to freeze-thaw cycles 
than others. This is illustrated by the high percent-
age of intensity changes seen in the 95
th and 99
th 
percentile of peaks (Table 2). Further, analysis of 
the change in peak intensity by mass range shows 
that on average, higher mass peaks lose intensity 
while peaks in the smaller mass ranges show mod-
estly increased peak intensity as would be expected 
if the larger proteins were more susceptible to 
degradation. Based on these results, freeze-thawing 
a sample more than twice could begin to compro-
mise data quality by interfering with peak detec-
tion. Differences in peak intensity between disease 
states may not be evident if peaks are signiﬁ  cantly 
degraded by multiple freeze-thaw exposures. Fur-
ther, these results indicate that it would be inadvis-
able to use control samples that had been 
freeze-thawed a different number of times than the 
cases (i.e., controls from a different study) as par-
ticularly sensitive peaks might track with freeze-
thaw treatment rather than disease status. To our 
knowledge, this is the ﬁ  rst study to report how 
repeated freeze-thaw cycles can affect plasma mass 
spectrometry data quality.
We also investigated how long-term storage at 
–70°C inﬂ  uenced MADLI mass spectrometry data 
using samples that were frozen in 1992/1993 com-
pared to samples frozen 4 years later. While it is 
possible that there may have been some protein 
degradation that has occurred in the ﬁ  ve years since 
the 1996/97 samples were frozen, samples stored 
in a similar manner represent some of the best 
samples available for biomarker discovery work. 
Thus, we feel that these samples correspond to a 
time frame that is representative of the samples 
that we, and others, are using for disease marker 
identiﬁ  cation.
The MALDI measurements in the range of 
1,000 to 40,000m/z of the 1992/93 plasma samples 
showed no difference in the number of peaks com-
pared to the 1996/97 samples that were collected 
four years more recently. Comparing the number 
of peaks by mass ranges also reveals no differences 
Table 4: Peak number, variation and correlation of plasma samples 
from 1992/93 compared to 1996/97
1992/93 
(25
th, 75
th 
percentile)
1996/97 
(25
th, 75
th 
percentile)
Number of 
peaks
636 
(611, 666)
630 
(596, 673)
Coefﬁ  cient of 
Variation
14.6% 
(11.6%, 26.3%)
13.7% 
(11.3%, 26.5%)
Coefﬁ  cient of 
Variation using 
5 replicates
11.1% 
(8.0%, 18.8%)
10.2% 
(7.9%, 19.6%)
Correlation
0.40 
(0.32, 0.47)
Table 5: Comparison of the number of peaks at different mass/charge 
ranges in the 1992/93 and 1996/97 samples
Mass/charge 
range 
Median number of peaks 
(25
th, 75
th percentile) 
1992/93 1996/97
 5,000 174 
(163,191)
177 
(163,194)
5,000 - 10,000 58 
(53,65)
57 
(53,63)
10,000
401 
(386,426)
395 
(376,421)Mitchell, Yasui, Li et al
103 Cancer Informatics 2005:1
between the two sample years. If long-term storage 
at –70°C caused signiﬁ  cant protein degradation, 
one would expect to see more small peaks in the 
1992/93 samples than in the newer, 1996/97 
samples. However, this is not the case, suggesting 
that the length of freezer storage at –70°C in a study 
will not affect the quality of MALDI assays. Fur-
ther, using all ﬁ  ve replicates, the MALDI measure-
ments of the 1992/93 plasma samples had a median 
CV of 11.1%, which does not differ appreciably 
from the median CV of 10.2% for the 1996/97 
plasma samples. This indicates that well over 1,000 
peaks (of the total of 2,153 identified) were 
measured with a CV of 15%. As described above, 
this level of CV is definitely acceptable and 
compares well with many laboratory assays used 
in biomedical research.
The within-subject correlation of the two MALDI 
measurements taken 4 years apart was moderate (a 
median correlation of 0.40). This is consistent with 
our expectation that the longitudinal protein proﬁ  le 
of a subject will remain stable to some degree, but 
also is consistent with the fact that the proteome is 
dynamic and is inﬂ  uenced by a variety of factors 
including physiological changes (e.g., the aging 
process), diet, and transient exposures, all of which 
could vary appreciably over 4 years, particularly in 
this aging population. Further, while the samples 
were randomized and run on the same plate on the 
same day, instrument variation could also reduce 
the correlation between the samples.
Consistent with our results, a previous study 
found no change in nine risk factors for anthero-
sclerosis and thrombosis in plasma pools that had 
been stored at –70°C for various lengths of time 
(Lewis et al. 2001). While the study by Lewis et 
al used functional or immunoassays to measure 
retention of epitopes over time, by taking advan-
tage of the properties of mass spectrometry we 
were able to evaluate long-term storage effects on 
the protein stability of plasma samples. This is the 
ﬁ  rst study, to our knowledge, to report on the 
effects of long-term storage on a broad screen of 
the human plasma proteome.
In conclusion, it is evident from our freeze-thaw 
experimental data that repeatedly thawing samples 
can lead to protein degradation. In fact, repeated 
thawing appears to be more problematic than long-
term storage at –70°C in terms of maintenance of 
peak number and intensity. This finding is 
encouraging because the number of freeze-thaw 
cycles a sample is subjected to can be monitored 
and controlled by early sample aliquoting whereas 
the length of sample storage is often not something 
that can be changed. The use of plasma samples 
from longitudinal studies may be an ideal approach 
to biomarker discovery as they often allow a person 
to be their own pre-disease control, reducing the 
genetic variation that is inherent in population 
based studies. Based on these results, the minimal 
damage to the integrity of the plasma proteome 
with long-term storage does not outweigh the 
benefits that maybe generated by using these 
samples.
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